Citadel Advisors
INDP icon

Citadel Advisors’s Indaptus Therapeutics INDP Stock Holding History

Citadel Advisors’s Portfolio INDP Stock Details INDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$71K Buy
+39,018
New +$83.7K ﹤0.01% 12243
2024
Q4 		– Sell
-550
Closed -$19.1K – 14913
2024
Q3 		$19.1K Sell
550
-243
-31% -$11.9K ﹤0.01% 12805
2024
Q2 		$47.1K Buy
+793
New +$52.6K ﹤0.01% 11832
2024
Q1 		– Sell
-590
Closed -$29.2K – 14999
2023
Q4 		$29.2K Buy
+590
New +$37.1K ﹤0.01% 12287
2022
Q4 		– Sell
-389
Closed -$24K – 15152
2022
Q3 		$24K Buy
+389
New +$30.3K ﹤0.01% 12003
2021
Q4 		– Sell
-508
Closed -$111K – 14253
2021
Q3 		$111K Buy
508
+398
+362% +$115K ﹤0.01% 12744
2021
Q2 		$43K Sell
110
-90
-45% -$39.6K ﹤0.01% 13388
2021
Q1 		$98K Sell
200
-215
-52% -$113K ﹤0.01% 12495
2020
Q4 		$160K Buy
415
+392
+1,704% +$171K ﹤0.01% 9901
2020
Q3 		$13K Sell
23
-109
-83% -$80.1K ﹤0.01% 9922
2020
Q2 		$84K Buy
132
+78
+144% +$48.2K ﹤0.01% 9086
2020
Q1 		$23K Buy
54
+36
+200% +$27.2K ﹤0.01% 9263
2019
Q4 		$20K Sell
18
-20
-53% -$27.6K ﹤0.01% 8937
2019
Q3 		$63K Buy
+38
New +$113K ﹤0.01% 8647

Other funds holding INDP

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
Carson Wealth (CWM LLC)
Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

Citadel Advisors's INDP Position: Q1 2026 in Review

Citadel Advisors opened a new position in Indaptus Therapeutics (INDP) in Q1 2026: 39,018 shares worth $71K. The stake represents ﹤0.01% of the portfolio and ranks #12243 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in INDP as recently as Q3 2024.

Citadel Advisors first reported a position in INDP in Q3 2019 and has held it in 14 quarters since. The position peaked at $160K in Q4 2020. 6 funds tracked by Wall St. Rank hold INDP as of Q1 2026.

  • Citadel Advisors held 39,018 shares of Indaptus Therapeutics worth $71K as of Q1 2026.
  • Indaptus Therapeutics was a new Citadel Advisors position in Q1 2026.
  • Indaptus Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12243 holding.
  • Citadel Advisors first reported a position in Indaptus Therapeutics in Q3 2019 and has held it in 14 quarters since.
  • Citadel Advisors's Indaptus Therapeutics position peaked at $160K in Q4 2020.
  • 6 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.